The Use of Leukotriene Inhibitors as Basic Therapy in Children with Bronchial Asthma

Leukotriene Inhibitors as Basic Therapy in Children with Bronchial Asthma

  • Zebo Norboboevna Sherova Clinical Pharmacology, Department of Family Medicine No. 2, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan.
  • Kamola Yuldasheva Normatova Clinical Pharmacology, Department of Family Medicine No. 2, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan.
  • Kamala Shakhamdamovna Shaabidova Clinical Pharmacology, Department of Family Medicine No. 2, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan.
Keywords: Leukotriene, Bronchial Asthma, Montelukast, Inflammatory, Glucocorticosteroids


In the pharmacotherapy of bronchial asthma, a ”step-by-step” approach is recommended, which includes an increase or decrease in the volume of therapy, depending on the severity of clinical symptoms. In complex therapy, it is possible to use non-drug methods of treatment, although the effectiveness of some of them is debatable and needs further study. To achieve this goal, children over the age of 3 years (the group of patients consisted of 26 children) with different forms and degrees of severity of bronchial asthma were included in the study. Patients of       the main group took L-Montus (montelukast), children of the ketotifen comparison group. Leukotriene receptor antagonists (montelukast, zafirlukast) are the first mediator-specific therapy of AD and represent a new therapeutic class of drugs in the treatment of the disease. The effectiveness of leukotriene receptor antagonists has been proven in randomized clinical trials among adults and children with bronchial asthma. Leukotriene receptor blockers, in particular L-Montus relieves the symptoms of AD and is a drug for the basic therapy of this disease, leads to a significant improvement in control, reduces the frequency of exacerbations of AD caused by viral infection in children aged 3-5 years. It has an anti-inflammatory effect, complementary to the action of glucocorticosteroids.


Van Mason J, Portnoy JM. Immunologic strategies for prevention of asthma. J Allergy Clin Immunol Pract. 2020;8(3):834–847. Available from:

Rai SP, Patil AP, Vardhan V, Marwah V, Pethe M, Pandey IM. Best Treatment Guidelines For Bronchial Asthma. Med J Armed Forces India. 2007;63(3):264–268. Available from:

Guilbert TW, Bacharier LB, Fitzpatrick AM. Severe asthma in children. J Allergy Clin Immunol Pract. 2014;2(5):489–500. Available from:

Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73. Available from:

Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy. 2000;30:2–5. Available from:

Veremchuk LV, Yankova VI, Vitkina TI, Nazarenko AV, Golokhvast KS. Urban air pollution, climate and its impact on asthma morbidity. Asian Pac J Trop Biomed. 2016;6(1):76–85. Available from:

Moorman JE, Zahran H, Truman BI, Molla MT. Centers for Disease Control and Prevention (CDC). MMWR Surveill Summ. 2006;60:84–90.

Moonie SA, Sterling DA, Figgs L, Castro M. Asthma status and severity affects missed school days. J Sch Health. 2006;76(1):18–24. Available from:

Lang A, Carlsen KH, Haaland G, Devulapalli CS, Munthe-Kaas M, Mowinckel P, et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy. 2008;63(8):1054– 60. Available from:

Hirai K, Tanaka A, Homma T, Kawahara T, Oda N, Mikuni H, et al. Prevalence and clinical features of Asthma-COPD overlap in patients with COPD not using inhaled corticosteroids. Allergol Int. 2021;70(1):134–135. Available from:

Bellin MH, Osteen P, Kub J, Bollinger ME, Tsoukleris M, Chaikind L, et al. Stress and Quality of Life in Urban Caregivers of Children With Poorly Controlled Asthma: A Longitudinal Analysis. J Pediatr Health Care. 2015;29(6):536–346. Available from:

Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19(1):61–67. Available from:

Zahran HS, Bailey CM, Damon SA, Garbe PL, Breysse PN. Vital Signs: Asthma in Children — United States, 2001– 2016. MMWR Morb Mortal Wkly Rep. 2018;67(5):149–155. Available from:

Puig-Junoy J, Pascual-Argente N. Socioeconomic costs of asthma in the European Union, United States and Canada: A systematic review. Rev Esp Salud Publica. 2009;p. 91.

Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitzgerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–178. Available from:

Zyryanov SK, Diyakov IN, Avdeev SN. Pharmacoeconomic analysis of using biological agents for uncontrolled moderate- to-severe atopic asthma in the Russian Federation. FAR- MAKOEKONOMIKA. 2020;12(4):268–78. Available from:

Lemanek K. Adherence issues in the medical management of asthma. J Pediatr Psychol. 1990;15(4):437–58. Available from:

Kohlboeck G, Koletzko S, Bauer CP, Berg V, Berdel A, Krämer D, et al. GINI-plus Study groups. Association of atopic and non-atopic asthma with emotional symptoms in school children. Pediatr Allergy Immunol. 2013;24(3):230–236. Available from:

Goodwin RD, Fergusson DM, Horwood LJ. Asthma and depressive and anxiety disorders among young persons in the community. Psychol Med. 2004;34(8):1465–1474. Available from:

Feldman JM, Steinberg D, Kutner H, Eisenberg N, Hottinger K, Sidora-Arcoleo K, et al. Perception of pulmonary function and asthma control: the differential role of child versus caregiver anxiety and depression. J Pediatr Psychol. 2013;38(10):1091– 1100. Available from: